Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

Journal of Clinical Oncology

Volumn 26, Issue 28, 2008, Pages 4617-4625

  Burdett, Sarah ^a   Burdett, S ^b   Stephens, R ^b   Stewart, L ^b   Tierney, J ^b   Auperin, A ^c   Le Chevalier, T ^c   Le Pechoux, C ^c   Pignon, J P ^c   Arriagada, R ^d,e   Higgins, J ^e   Johnson, D ^f   Van Meerbeeck, J ^g   Parmar, M ^b   Souhami, R ^h   Bell, D ⁱ   Cartei, G ^j   Cormier, Y ^k   Cullen, M ^l   Ganz, P ^m   Gridelli, C ⁿ   Kaasa, S ^o   Quoix, E ^p   Rapp, E ^m   Seymour, L ^q   Spiro, S ^r   Thatcher, N ^s   Tummarello, D ^t   Williams, C ^u   Williamson, I ^v   more..

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d KAROLINSKA INSTITUTE   (Sweden)

^e MRC BIOSTATISTICS UNIT   (United Kingdom)

^f VANDERBILT INGRAM CANCER CENTER   (United States)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ ROYAL NORTH SHORE HOSPITAL   (Australia)

^j International Academy of Environmental Sciences (IAES)   (Italy)

^k LAVAL UNIVERSITY   (Canada)

^l QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ S G MOSCATI HOSPITAL   (Italy)

^o TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^p Service de Pneumologie   (France)

^q QUEEN S UNIVERSITY   (Canada)

^r UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^s CHRISTIE HOSPITAL   (United Kingdom)

^t UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^u BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^v Aneurin Bevan University Health BoardClinical Research and Innovation Centre St Woolos Hospital   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFECT; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PALLIATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 53749097825     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.7162     Document Type: Review

References (35)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics, 2002. CA Cancer J Clin 55:74-108, 2005
2. Visbal AL, Leighl NB, Feld R, et al: Adjuvant chemotherapy for early stage non-small cell lung cancer. Chest 128:2933-2943, 2005
3. World Health Organization: Global cancer rates could increase by 50% to 15 million by 2020. http://www.who.int/mediacentre/news/releases/2003/pr27/en/
4. Greenlee RT, Murray T, Bolden S, et al: Cancer Statistics, 2000. CA Cancer J Clin 50:7-33, 2000
5. Rudd R: Chemotherapy in the treatment of non-small cell lung cancer. Respiratory Disease in Practice 7:12-14, 1991
6. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
7. Burdett S, Pignon JP, Stewart L: Chemotherapy in non-small cell lung cancer: An update of an IPD meta-analysis. J Thorac Cardiovasc Surg 129:1205, 2005
8. Dickersin K, Scherer R, Lefebvre C: Identifying relevant studies for systematic reviews. BMJ 309:1286-1291, 1994
9. Yusuf S, Peto R, Lewis J, et al: Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 27:335-371, 1985
10. Spiro SG, Rudd RM, Souhami RL, et al: Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life. Thorax 59:828-836, 2004
11. Parmar MKB, Machin D: Survival Analysis: A Practical Approach. Chichester, John Wiley and Sons Ltd, 1995
12. Higgins JPT, Thompson SG, Deeks JJ, et al: Measuring inconsistency in meta-analyses. BMJ 327:557-560, 2003
13. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. Journal of the American Statistical Association 53:457-481, 1958
14. Thongprasert S, Sanguanmitra P, Juthapan W, et al: Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 24:17-24, 1999
15. Gasparini S, Farabollini B, Isidori P, et al: Lonidamine, chemotherapy (cisplatin and etoposide) and chemotherapy plus lonidamine vs the best supportive care in the treatment of advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomised study. Lung Cancer 7:A383, 1991
16. Roszkowski K, Pluzanska A, Krzakowski M, et al: A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer. Lung Cancer 27:145-157, 2000
17. Woods RL, Williams CJ, Levi J, et al: A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61:608-611, 1990
18. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
19. Kaasa S, Lund E, Thorud E, et al: Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer 67:2443-2447, 1991
20. Cellerino R, Tummarello D, Guidi F, et al: A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small cell lung cancer. J Clin Oncol 9:1453-1461, 1991
21. Cartei G, Cartei F, Cantone A, et al: Cisplatin-cyclophosphamide- mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small cell lung cancer. J Natl Cancer Inst 85:794-800, 1993
22. Quoix É, Dietemann A, Charbonneau J, et al: Is cisplatinum-based chemotherapy useful in disseminated non-small-cell lung cancer? Report of a French multicenter randomized trial [in French]. Bull Cancer 78:341-346, 1991
23. Ganz PA, Figlin RA, Haskell CM, et al: Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference? Cancer 63:1271-1278, 1989
24. Cullen MH, Billingham LJ, Woodroffe CM, et al: Mitomycin, ifosfamide and cisplatin in resectable non-small cell lung: Effects on survival and quality of life. J Clin Oncol 17:3188-3194, 1999
25. Helsing M, Bergman B, Thaning L, et al: Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Eur J Cancer 34:1036-1044, 1998
26. Anderson G, Payne H: Response rate and toxicity of etoposide (VP-16) in squamous carcinoma of the lung: Report from the Lung Cancer Treatment Study Group. Semin Oncol 12:21-22, 1985 (suppl 2)
27. Elderly Lung Cancer Vinorelbine Italian Study Group: Effect of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 91:66-72, 1999
28. Anderson H, Hopwood P, Stephens RJ, et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome. Br J Cancer 83: 447-453, 2000
29. Ranson M, Davidson N, Nicolson M, et al: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92:1074-1080, 2000
30. Parmar MKB, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815-2834, 1998
31. Lilenbaum RC, Langenberg P, Dickersin K: Single agent versus combination chemotherapy in patients with advanced non-small cell lung carcinoma. Cancer 82:116-126, 1998
32. Hotta K, Matsuo K, Ueoka H, et al: Addition of platinum compounds to a new agent in patients with advanced non-small cell lung cancer: A literature based meta-analysis of randomised trials. Ann Oncol 15:1782-1789, 2004
33. Delbaldo C, Michiels S, Syz N, et al: Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small cell lung cancer. JAMA 292:470-484, 2004
34. Lilenbaum RC, Herndon JE II, List MA, et al: Single agent versus combination chemotherapy in advanced non-small cell lung cancer: The Cancer and Leukemia Group B (study 9730). J Clin Oncol 23:190 196, 2005
35. Gridelli C, Bareschino MA, Schettino C, et al: Erlotinib in non-small cell lung cancer treatment: Current status and future development. The Oncologist 12:840-849, 2007